-
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
09 May 2024 20:01 GMT
… pharmaceutical company focused on developing and commercializing treatments for … with phenylketonuria (PKU). An estimated 8,000 PKU patients … . Food and Drug Administration (FDA) for ET-400 … of discovering, developing and commercializing drugs that are …
-
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
07 May 2024 12:26 GMT
… the development and expedite the review of therapeutics to treat … FDA, and Orphan designation from the European Commission for the treatment … United Kingdom. In addition, trial sites in the United … are to assess the pharmacokinetics and efficacy of ECUR …
-
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript
03 May 2024 15:23 GMT
… FDA filing acceptance and priority review for a new drug … phenylketonuria, abbreviated as PKU, a patient population with limited treatment … excellence, so many treating physicians will have first … to our mission of developing and delivering transformative …
-
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
01 May 2024 20:05 GMT
… Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments … rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous …
-
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
30 Apr 2024 11:00 GMT
… innovative pharmaceutical company focused on developing and commercializing treatments for … S. Food and Drug Administration (FDA) for approval of … bringing this critical medication to children in … of discovering, developing and commercializing drugs that are …
-
Treatment of rare diseases in Bulgaria will be free but conditional and limited
29 Apr 2024 19:48 GMT
… autoimmune, are deprived of treatment with certain drugs. And we are talking … includes only three rare diseases: phenylketonuria, adrenocortical hyperplasia, and congenital … by the Association of Research Pharmaceutical Manufacturers in Bulgaria (ARPharM) …
-
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
29 Apr 2024 20:30 GMT
… ), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases … rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous …
-
Fierce Pharma Asia—Novartis reworks China ties; Neurocrine-Takeda med passes depression test; Enhertu nears key readout
26 Apr 2024 18:20 GMT
… .
2. Neurocrine-Takeda med reduces depression severity in … Pharmaceutical and Kind Pharmaceuticals. The settlement still allows Kind to develop … recalls 6 lots of PKU drug due to possible … dihydrochloride powder used to treat phenylketonuria due to potential …
-
Dr. Reddy's recalls 6 lots of PKU drug due to possible potency problems
25 Apr 2024 17:59 GMT
… dihydrochloride powder used to treat phenylketonuria (PKU) due to potential … and irreversible intellectual disability, developmental delay, and seizures. … another batch of the drug, simply called sapropterin … observations following an FDA inspection that found …
-
BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript
25 Apr 2024 01:50 GMT
… actions in the pharmaceutical market and developments by competitors and … our current leadership in treating achondroplasia and anticipated expansion … and effective medicines to treat rare skeletal disorders. … approved for the treatment of PKU, offset by lower …